Shanghai Junshi Biosciences Schedules 2025 Results Briefing for Investor Q&A

Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has issued an update.

Shanghai Junshi Biosciences Co., Ltd. has announced plans to hold its 2025 annual results briefing, following the disclosure of its 2025 annual report on the Shanghai Stock Exchange website on 14 March 2026. The online briefing will be held via the Shanghai Stock Exchange Roadshow Center on 27 March 2026, giving investors an opportunity to engage directly with management and deepen their understanding of the company’s 2025 operating results and financial performance.

Investors can submit questions in advance through the Roadshow Center’s question collection function or via email before the event, with the company pledging to address issues of broad interest during the session. The board emphasizes the accuracy and completeness of the information in the announcement, underscoring its commitment to regulatory transparency and investor communication as it reviews the past year’s performance.

The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.

More about Shanghai Junshi Biosciences Co., Ltd. Class H

Shanghai Junshi Biosciences Co., Ltd. is a China-based biopharmaceutical company listed in both Hong Kong and Shanghai, focused on developing and commercializing innovative therapies. The firm targets domestic and international healthcare markets, and its leadership includes a board of executive, non-executive and independent non-executive directors overseeing strategic and regulatory affairs.

Average Trading Volume: 3,229,471

Technical Sentiment Signal: Sell

Current Market Cap: HK$34.58B

See more insights into 1877 stock on TipRanks’ Stock Analysis page.